IBD Evidence

Symptom

Lívið við IBD: móð, pínu og ómæld partar

Remissión á pappír og remissión sum upplivað eru ymisk ting, og gapið er har flestu av byrðuni liggur.

Uppdatert 2 min lesing 26 tilvísingar Dokumentasjonsstyrkur 3/5

Gøta sjón av apotekshúsinum í Bautzen, Týsklandi
Fiver, der Hellseher · CC BY-SA 4.0 · Wikimedia Commons

Móður

Fatigue er millum tey mest ofta meldaðu symptomini í IBD og millum tey minst ofta viðgjørd. Tað heldur fram í einum stórum part av fólki, har inflamatiónin er stýrð, sum merkir, at tað er ikki bara ein merkir um sjúkuvirksemi.

Ávirkjarar eru millum annað anemi (jernmangul er nógv vanligur og rættanlegur), svefntruflanir, lyknivøttur, kronisk inflamatión, og sálarligur byrði av einum ófyrisigandi sjúku. Tey rættanlegu eru vert at fylgja upp á beinleiðis, tí eingin fer at taka tey upp fyri teg í einum fimtán-minuttum fundi, sum er miðvíst um calprotectin.

Fatigue byrði í IBD

Sálarheilsu

Angist og depresiónarhøttir í IBD yvirganga nógv bakgrundarhøttir. Tann augljósa forklaringin — at liva við einum ófyrisigandi, stigmatiseraðum, stundum pínandi sjúku er óhugnaligt — er veruligt og kanska ikki alt søgan, tá hugsað verður um inflamatóriskar og tarm-heilabrúkar leiðir sum eru viðgjørdar á okkara tarm-heilabrúkar vøttum.

Tað sum hevur týdning í praktiskum førum er, at hetta er viðgerandi og ofta missað. Sálarlig stuðul er ein partur av IBD viðgerð í evropeiskum leiðbeiningum og er ójavnt veittur.

Tað praktiska byrði

  • Angist fyri toalettum, sum avmarkar ferð, arbeiði og sosialt lív meira enn læknar vanligt meta.
  • Ófyrisigandi. At planleggja er torført, tá ein fløtt kann koma uttan fyrireiking.
  • Matarstýring. Persónligir ávirkjarar, eingin staðfest listi, og nógv mótstríðandi ráð — sí matur.
  • Arbeiði. Fatigue og bráðskund eru illa samanspæld við strikta arbeiðsmynstur.
  • Ferð. Lyknivøttur, mattrygd og atgongd — viðgjørt á okkara ferðarheilsuvøttum.

Epidemiologi

IBD frekvens er høg og stabil í Europa og Norðuramerika og vaksandi skarpt í nýtt industrialiseruðum londum. Tann geografiska mynstur er ein av sterkastu argumentunum fyri einum umhvørvisligum part — matur, hreinleiki, antibiotika og mikrobiomet eru øll kandidatar, og eingin er staðfest.

Vanlig spurningar

Hví eri eg burturdrigin, um eg eri í remissión?
Troyttleiki heldur ofta fram, eftir at bólgan er stjórnað. Kanna ferritin og B12 fyrst; tey eru vanlig, rættanleg og verða ofta oversitin.
Er stress orsøk til uppblussanina hjá mær?
Stress kann rímiliga ávirka tekin, og prógvið fyri, at tað orsakar bólgu, er veikari enn tað vanliga fólkaskilið. Tað er ikki tín skyld.
Fer eg at tørva ein skurðaðgerð?
Ein munandi minniluti ger tað, og partin er fallin, sum virkin viðgerð er komin skjótari í gongd — sí viðgerð.
Kann eg ferðast?
Ja, við ætlanargerð um lyv, tryggingar og matartrygd.
Fyrstu hædd apotek á Teltower Damm í Berlin-Zehlendorf, Týskland
Singlespeedfahrer · CC0 · Wikimedia Commons

Tengt lesing

Evidensin fyri hesa síðu Ein stakkur bar, sum vísir samansetingina av teimum 20 útgávunum, ið eru nevndar á hesi síðu, eftir rannsóknartypi. 14352meta-analysis (14)randomised trial (3)review (5)other (2)
24 útgávur, 2015–2025. Hetta er ein blanding av bæði royndum og samansetingum, sum er støðan, har frá ein áheitan um orsøkin er skilvís. Kelda: egnu tilvísingalistin á hesi síðu, niðanfyri.

Viðmerkingar

Hver einasta tilvísing niðanfyri bendir til upprunaliga peer-reviewed skjalið á PubMed ella gjøgnum DOI. Einki her er ein staðfesting fyri læknaligt ráð.

  1. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  2. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  3. Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns Steinmann M, Lampe D, Grosser J, et al. · Infection · 2024 · Meta-analysis DOIPubMed 38236326Full text
  4. Acute severe ulcerative colitis trials: the past, the present and the future Honap S, Jairath V, Sands BE, et al. · Gut · 2024 · Systematic review DOIPubMed 38834296Full text
  5. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses Buie MJ, Quan J, Windsor JW, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · Meta-analysis DOIPubMed 35863682
  6. Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease Valvano M, Capannolo A, Cesaro N, et al. · Nutrients · 2023 · Systematic review DOIPubMed 37686856Full text
  7. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review Kuenzig ME, Fung SG, Marderfeld L, et al. · Gastroenterology · 2022 · Systematic review DOIPubMed 34995526
  8. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis Barberio B, Zamani M, Black CJ, et al. · The lancet. Gastroenterology & hepatology · 2021 · Meta-analysis DOIPubMed 33721557
  9. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD Turner D, Ricciuto A, Lewis A, et al. · Gastroenterology · 2021 · Systematic review DOIPubMed 33359090
  10. ACG Clinical Guideline: Management of Irritable Bowel Syndrome Lacy BE, Pimentel M, Brenner DM, et al. · The American journal of gastroenterology · 2021 · Clinical guideline DOIPubMed 33315591
  11. Pediatric Psoriasis Comorbidities Kittler NW, Cordoro KM · Skin therapy letter · 2020 · Clinical guideline PubMed 33196156
  12. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses-Part I Knowles SR, Graff LA, Wilding H, et al. · Inflammatory bowel diseases · 2018 · Meta-analysis DOIPubMed 29562277
  13. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies Ng SC, Shi HY, Hamidi N, et al. · Lancet (London, England) · 2017 · Systematic review DOIPubMed 29050646
  14. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target Peyrin-Biroulet L, Sandborn W, Sands BE, et al. · The American journal of gastroenterology · 2015 · Systematic review DOIPubMed 26303131
  15. Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study Ferrante M, D'Haens G, Jairath V, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39581202
  16. Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme Danese S, Dignass A, Matsuoka K, et al. · Journal of Crohn's & colitis · 2024 · Randomised controlled trial DOIPubMed 38869019Full text
  17. Acceptance and Commitment Therapy for Adults Living With Inflammatory Bowel Disease and Distress: A Randomized Controlled Trial Naude C, Skvarc D, Maunick B, et al. · The American journal of gastroenterology · 2024 · Randomised controlled trial DOIPubMed 39162706Full text
  18. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial Cox SR, Lindsay JO, Fromentin S, et al. · Gastroenterology · 2020 · Randomised controlled trial DOIPubMed 31586453
  19. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. · The New England journal of medicine · 2019 · Randomised controlled trial DOIPubMed 31553834
  20. Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies Caron B, Honap S, Peyrin-Biroulet L · Journal of Crohn's & colitis · 2024 · Review DOIPubMed 39475082Full text
  21. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life Nguyen TV, Damiani G, Orenstein LAV, et al. · Journal of the European Academy of Dermatology and Venereology : JEADV · 2021 · Review DOIPubMed 32460374
  22. Iron Deficiency Anemia in Inflammatory Bowel Diseases-A Narrative Review Mahadea D, Adamczewska E, Ratajczak AE, et al. · Nutrients · 2021 · Review DOIPubMed 34836263Full text
  23. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities Elmets CA, Leonardi CL, Davis DMR, et al. · Journal of the American Academy of Dermatology · 2019 · Review DOIPubMed 30772097
  24. Fatigue in inflammatory bowel disease Grimstad T, Norheim KB · Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke · 2016 · Review DOIPubMed 27830906
  25. Global evolution of inflammatory bowel disease across epidemiologic stages Hracs L, Windsor JW, Gorospe J, et al. · Nature · 2025 · Journal article DOIPubMed 40307548Full text
  26. Psychological symptoms and quality of life in patients with inflammatory bowel disease in China: A multicenter study Zhang J, Liu C, An P, et al. · United European gastroenterology journal · 2024 · Journal article DOIPubMed 38315582Full text

Henda síða varð sjálvvirkandi týdd úr enskt. Tilvísingarnar og tølini eru óbroytt. Les upprunaliga enska útgávuna um nakað lesist undarliga. Les upprunaliga enska útgávuna